Guillain-Barre Syndrome Market

Market Overview:

The 7 major Guillain-Barre syndrome markets reached a value of US$ 429.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 660.8 Million by 2034, exhibiting a growth rate (CAGR) of 3.99% during 2024-2034.

The Guillain-Barre syndrome market has been comprehensively analyzed in IMARC’s new report titled “Guillain-Barre Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Guillain-Barre syndrome (GBS) is a rare autoimmune disorder in which the body's immune system attacks the nerves. This leads to inflammation and damage of the nerves, which results in muscle weakness and sometimes paralysis. GBS can affect the nerves in the arms, legs, face, and respiratory system, and in severe cases, it can lead to life-threatening complications. The common symptoms of GBS typically begin with muscle weakness in the legs and progress upward, eventually affecting the arms and face. Other symptoms include tingling, numbness, difficulty in speaking or swallowing, and breathing problems. The diagnosis of Guillain-Barre syndrome (GBS) is based on a combination of clinical signs and symptoms, and laboratory tests. A physical examination is conducted to assess muscle strength, reflexes, and sensation. Nerve conduction tests are also utilized to measure the electrical activity of nerves and confirm the diagnosis of GBS. Additional tests, such as an electrocardiogram (ECG) or an electromyogram (EMG), can be conducted to rule out other potential causes of the symptoms.

The increasing prevalence of several respiratory and gastrointestinal infections is primarily driving the global Guillain-Barre syndrome market. In addition to this, the expanding geriatric population, who are more sensitive to infectious diseases due to their low immunity, is also bolstering the market growth. Moreover, the rising consumer awareness regarding the importance of early treatment for GBS that aids in reducing the severity of symptoms and improving outcomes is further augmenting the global market. Besides this, the inflating utilization of plasmapheresis to treat GBS is also creating a positive outlook for the market. Plasmapheresis works by removing the antibodies attacking the nerves, which helps to reduce inflammation and damage to the nerves. Furthermore, the widespread adoption of several medications, such as analgesics, anticonvulsants, low-molecular-weight heparin, etc., to alleviate symptoms and post-treatment complications of Guillain–Barre syndrome is also bolstering the market growth. Apart from this, the escalating usage of various physical therapies to help in preventing muscle weakness, maintaining range of motion, and improving muscle strength is further acting as a significant growth-inducing factor. Additionally, the emerging popularity of intravenous immunoglobulin (IVIG) as a first-line treatment among patients who are not candidates for plasma exchange is expected to drive the global Guillain-Barre syndrome market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the Guillain-Barre syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Guillain-Barre syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Guillain-Barre syndrome market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Guillain-Barre syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Guillain-Barre syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Guillain-Barre syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Guillain-Barre syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Guillain-Barre syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Guillain-Barre syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Guillain-Barre syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Guillain-Barre syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Guillain-Barre syndrome by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Guillain-Barre syndrome by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with Guillain-Barre syndrome across the seven major markets?
• What is the size of the Guillain-Barre syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Guillain-Barre syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Guillain-Barre Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Guillain-Barre syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Guillain-Barre syndrome market?
• What are the key regulatory events related to the Guillain-Barre syndrome market?
• What is the structure of clinical trial landscape by status related to the Guillain-Barre syndrome market?
• What is the structure of clinical trial landscape by phase related to the Guillain-Barre syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Guillain-Barre syndrome market?